Report / Paper metadata
Xpert® bladder Cancer monitor urine test for non-muscle-invasive bladder cancer surveillance: a prospective clinical trial.
In a prospective bladder-cancer surveillance study, a urine biomarker test detected more confirmed recurrences than urine cytology. Its high negative predictive value does not by itself show that cystoscopy can safely be removed from follow-up.
What was tested?
The study assessed Xpert Bladder Cancer Monitor as a non-invasive aid for people being followed for non-muscle-invasive bladder cancer. It was conducted at one centre, with blinding and no assigned treatment intervention. Over 18 months, 193 patients contributed 304 follow-up visits.
How did the tests compare?
The abstract describes 24 histologically confirmed recurrences among 221 tested cases. Twenty of those recurrences had a positive biomarker test, compared with eight positive cytology results. Reported sensitivity was 83.3% for the biomarker test and 33.3% for cytology, with p = 0.0015. These are study-specific estimates, not a guarantee for an individual test.
What does a positive result mean here?
The positive predictive value was 27.78%, with a 95% confidence interval from 17.43% to 38.12%. In this tested group, a positive test did not usually correspond to a confirmed recurrence. Positive results therefore need interpretation within the surveillance pathway, not automatic treatment or a diagnosis based on the test alone.
What does a negative result mean here?
The negative predictive value was 97.32%, with a 95% confidence interval from 94.72% to 99.91%. Predictive values depend on the tested population and how common recurrence is. A high value in this study is not evidence that every negative result excludes cancer in a different setting.
What remains unanswered?
The abstract supports a comparison with cytology but does not establish that replacing cystoscopy with the urine test is safe. The study's single-centre setting and repeat follow-up visits also matter when reading its denominators. This explanation is based on the abstract, not a complete review of the surveillance protocol or a recommendation to change follow-up care.
- Journal
- Clinica chimica acta; international journal of clinical chemistry
- Kind
- Paper metadata
- Identifier
- PMID 42285342